(PharmaNewsWire.Com, July 05, 2017 ) Celiac disease is an autoimmune inflammatory disease of the small intestine, which is triggered by intake of gluten from wheat and other sources through our food. Presently, there is no specific drug approved for celiac disease, and the first line of treatment is completely dominated by a gluten-free diet. There are few anti-inflammatory and immunosuppressant drugs and nutritional supplements that are used as off-label therapy in celiac disease. All these off-label therapies are considered as second-line of treatment.
The report covers the present scenario and the growth prospects of the global celiac disease drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography: • Americas • APAC • EMEA
Publisher's report, Global Celiac Disease Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors • F. Hoffmann-La Roche • Johnson & Johnson • Merck • Pfizer
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
